Mammograms showing a normal breast (left) and a breast with cancer (right, white arrows). Credit: Bakerstmd.

Generon BioMed has reported positive results from a Phase III trial of F-627 for the treatment of women with breast cancer.

The global, double-blind, placebo controlled trial was led by the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It included 122 women with stage II-IV breast cancer receiving myelotoxic chemotherapy.

Results showed that subcutaneous administration of F-627 reduced the duration of Grade 4 or severe neutropenia in the trial’s chemotherapy cycle I.

Administration of F-627 also reduced the incidence and shorter duration of Grade IIII, Grade III and Grade II neutropenia.

“Generon is committed to bringing innovative oncology therapies to patients in China and the world.”

The trial showed that F-627 significantly reduced the incidence of febrile neutropenia (FN) among the subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

F-627 was also found to be safe and well tolerated with no deaths, no injection site reactions and reduced gastrointestinal after effects (AEs).

Generon BioMed chief medical officer Dr William Daley said: “This is yet another milestone and goal for Generon this year and is a significant step towards our mission of innovating for life.

“Generon is committed to bringing innovative oncology therapies to patients in China and the world.”

F-627 is a recombinant human Granulocyte Colony Stimulating Factor (rhG-CSF) protein developed for use as a preventive management of neutropenia.

Generon has used its Dimeric Cytokine (DiKine) technology to create F-627, which features an immunoglobulin-like dimeric structure.